INTERSTITIAL LUNG DISEASES
Clinical trials for INTERSTITIAL LUNG DISEASES explained in plain language.
Never miss a new study
Get alerted when new INTERSTITIAL LUNG DISEASES trials appear
Sign up with your email to follow new studies for INTERSTITIAL LUNG DISEASES, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New study tracks how well nintedanib works over time for scleroderma lung disease
Disease control OngoingThis study follows 2,000 people with systemic sclerosis (scleroderma) who have lung disease and are taking the drug nintedanib (Ofev®). Researchers want to see how the drug affects lung function, quality of life, and survival over the long term. The study is observational, meanin…
Matched conditions: INTERSTITIAL LUNG DISEASES
Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 23, 2026 11:57 UTC
-
New drug hope for lung scarring: anlotinib trial underway
Disease control OngoingThis study tests whether anlotinib capsules can help people with idiopathic pulmonary fibrosis (IPF) or progressive fibrosis-interstitial lung diseases (PF-ILDs), conditions that cause lung scarring and make breathing hard. About 30 adults aged 40-85 will receive either anlotinib…
Matched conditions: INTERSTITIAL LUNG DISEASES
Phase: PHASE2 • Sponsor: First Affiliated Hospital of Wenzhou Medical University • Aim: Disease control
Last updated Jun 17, 2026 12:09 UTC
-
Lung cancer and scarred lungs: a dangerous duo under the microscope
Knowledge-focused OngoingThis study examines how well immunotherapy works for people with both lung cancer and pulmonary fibrosis (scarred lungs). Researchers will compare 200 patients with both conditions to similar patients without scarring, tracking survival and side effects. They also analyze tumor t…
Matched conditions: INTERSTITIAL LUNG DISEASES
Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Knowledge-focused
Last updated Jun 16, 2026 12:54 UTC